Abstract
Many issues remain unresolved about antipsychotic drugs. Their therapeutic potency scales with affinity for dopamine D2 receptors, but there are indications that they act indirectly, with dopamine D1 receptors (and others) as possible ultimate targets. Classical neuroleptic drugs disinhibit striatal cholinergic interneurones and increase acetyl choline release. Their effects may then depend on stimulation of muscarinic receptors on principle striatal neurones (M4 receptors, with reduction of cAMP formation, for therapeutic effects; M1 receptors for motor side effects). Many psychotic patients do not benefit from neuroleptic drugs, or develop resistance to them during prolonged treatment, but respond well to clozapine. For patients who do respond, there is a wide ( > ten-fold) range in optimal doses. Refractoriness or low sensitivity to antipsychotic effects (and other pathologies) could then arise from low density of cholinergic interneurones. Clozapine probably owes its special actions to direct stimulation of M4 receptors, a mechanism available when indirect action is lost.
Keywords: Antipsychotic drugs, neuroleptic drugs, cholinergic interneurones, D1 receptors, D2 receptors, muscarinic M1 receptors, muscarinic M4 receptors, neuroleptic threshold, atypical antipsychotic agents
Current Neuropharmacology
Title: Mechanisms of Action of Antipsychotic Drugs of Different Classes, Refractoriness to Therapeutic Effects of Classical Neuroleptics, and Individual Variation in Sensitivity to their Actions: PART I
Volume: 7 Issue: 4
Author(s): R. Miller
Affiliation:
Keywords: Antipsychotic drugs, neuroleptic drugs, cholinergic interneurones, D1 receptors, D2 receptors, muscarinic M1 receptors, muscarinic M4 receptors, neuroleptic threshold, atypical antipsychotic agents
Abstract: Many issues remain unresolved about antipsychotic drugs. Their therapeutic potency scales with affinity for dopamine D2 receptors, but there are indications that they act indirectly, with dopamine D1 receptors (and others) as possible ultimate targets. Classical neuroleptic drugs disinhibit striatal cholinergic interneurones and increase acetyl choline release. Their effects may then depend on stimulation of muscarinic receptors on principle striatal neurones (M4 receptors, with reduction of cAMP formation, for therapeutic effects; M1 receptors for motor side effects). Many psychotic patients do not benefit from neuroleptic drugs, or develop resistance to them during prolonged treatment, but respond well to clozapine. For patients who do respond, there is a wide ( > ten-fold) range in optimal doses. Refractoriness or low sensitivity to antipsychotic effects (and other pathologies) could then arise from low density of cholinergic interneurones. Clozapine probably owes its special actions to direct stimulation of M4 receptors, a mechanism available when indirect action is lost.
Export Options
About this article
Cite this article as:
Miller R., Mechanisms of Action of Antipsychotic Drugs of Different Classes, Refractoriness to Therapeutic Effects of Classical Neuroleptics, and Individual Variation in Sensitivity to their Actions: PART I, Current Neuropharmacology 2009; 7 (4) . https://dx.doi.org/10.2174/157015909790031229
DOI https://dx.doi.org/10.2174/157015909790031229 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Novel Therapeutic Effects of the Anti-Convulsant, Zonisamide, on Parkinsons Disease
Current Pharmaceutical Design Functional Selectivity in Cannabinoid Signaling
Current Molecular Pharmacology On the Pathogenesis and Neuroprotective Treatment of Parkinson Disease: What have we Learned from the Genetic Forms of this Disease?
Current Medicinal Chemistry Carbonic Anhydrase Inhibitors
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Effects of Yokukansan, a Japanese Kampo Medicine for Symptoms Associated Autism Spectrum Disorder
CNS & Neurological Disorders - Drug Targets Deprescribing for Psychiatry: The Right Prescription?
Current Psychiatry Reviews Safety Profile of the Use of Second Generation Antipsychotics in the Child and Adolescent Population
Current Psychopharmacology Etiopathogenesis and Treatment of Parkinsons Disease
Current Topics in Medicinal Chemistry Innovations to Control the Environment for Persons with Movement Disorders: Support in Home Care
Recent Patents on Biomedical Engineering (Discontinued) Genetic Anomalies of the Respiratory Tract
Current Respiratory Medicine Reviews Effects of Antipsychotics on the BDNF in Schizophrenia
Current Medicinal Chemistry Neuropharmacology of Cannabinoid System: From Basic Science to Clinical Applications
Current Neuropharmacology Herb-Drug Interactions in Neurological Disorders: A Critical Appraisal
Current Drug Metabolism <i>Withania somnifera</i> in Neurological Disorders: Ethnopharmacological Evidence, Mechanism of Action and its Progress in Delivery Systems
Current Drug Metabolism Clozapine Safety, 35 Years Later
Current Drug Safety Dietary Phytoestrogens: Neuroprotective Role in Parkinson’s Disease
Current Neurovascular Research Positive Allosteric Modulators (PAMs) of Metabotropic Glutamate Receptor 5 (mGluR5) Attenuate Microglial Activation
CNS & Neurological Disorders - Drug Targets Controversies of Dopamine Agonists: Somnolence, Cardiac Valvulopathy and Repetitive Behaviors
Current Drug Therapy Small Molecule Efflux Pump Inhibitors in Mycobacterium tuberculosis: A Rational Drug Design Perspective
Mini-Reviews in Medicinal Chemistry Antipsychotic Augmentation Strategies to Ameliorate Negative and Cognitive Symptoms in Schizophrenia; Implications for Future Research
Central Nervous System Agents in Medicinal Chemistry